Expert Outlook: CytoSorbents Through The Eyes Of 5 Analysts
Portfolio Pulse from Benzinga Insights
CytoSorbents (NASDAQ:CTSO) has received mixed analyst ratings over the past three months, with a majority being bullish. The average 12-month price target has increased by 5.81% to $8.2. The company shows positive revenue growth but faces challenges with a high debt-to-equity ratio.
October 22, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CytoSorbents has received predominantly bullish ratings from analysts, with an average price target increase to $8.2. The company shows positive revenue growth but struggles with high debt levels.
The majority of analysts have a bullish outlook on CytoSorbents, with a significant increase in the average price target, indicating positive sentiment. However, the company's high debt-to-equity ratio could pose financial challenges, which investors should monitor.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100